Impact of Genomics on Medicine

Corporate Sponsor:

Corporate Support:

Sponsoring Publications:
Genome Letters Genomics and Proteomics American Journal of Pharmacogenomics Pharmacogenomics PharmaGenomics Scientific Computing World
Reception Sponsor:

Recent developments in genomics have highlighted the importance of a genomic approach to drug development, as the tools are moving from the discovery of novel targets for therapeutic intervention to prioritization of targets and compound selection against those targets. Genomics has allowed a means of constructing biological pathways by integrating genomic and proteomic expression information in order to identify key components within those pathways. This meeting will highlight the importance of a genomic approach to drug development and estimate the actual benefit of integrating genomic data into clinical practice.

SCIENTIFIC ADVISORS
Dr. Colin W. Dykes, Variagenics, Inc.
Dr. Trevor Nicholls, Oxagen Ltd.
Dr. Norman J.W. Russell, Lynx Therapeutics, Inc.
Dr. A. Donny Strosberg, Hybrigenics
Dr. Mathias Uhlén, Royal Institute of Technology
Dr. Edward D. Zanders, De Novo Pharmaceuticals Ltd.

SPEAKERS
Prof. Graham Boulnois, Schroder Ventures Life Sciences
Dr. Les Browne, Iconix (in collaboration with Incyte Genomics)
Dr. Robert A. Coleman, Pharmagene plc
Dr. Ariel Darvasi, IDgene Pharmaceuticals Ltd.
Dr. Cord E. Dohrmann, DeveloGen AG
Dr. Mary E. Donlan, Accelrys
Dr. Michael Famulok, Rheinische Friedrich-Wilhelms Universität
Dr. Igor Fisch, Swiss Federal Institute of Technology and Selexis SA
Dr. Cori Gorman, Biolog
Dr. Struan Grant, deCODE genetics
Dr. Guido Grandi, Chiron Vaccines
Dr. Richard Grosse, InGene, Institute of Genetic Medicine GmbH
Dr. J. Peter Halle, Switch Biotech AG
Dr. Udo Heinemann, Max-Delbruck-Centrum für Molekulare Medizin
Dr. Andres Kriete, Tissues Informatics, Inc.
Dr. Magnus Larsson, Royal Institute of Technology
Dr. Björn Löwenadler, Arexis AB
Prof. Hermann Luebbert, Biofrontera Pharmaceuticals AG
Dr. Peer R.E. Mittl, University of Zürich
Dr. Trevor Nicholls, Oxagen Ltd.
Dr. Martin Norin, Biovitrum
Dr. John Overington, Inpharmatica
Dr. A. Donny Strosberg, Hybrigenics
Dr. Peter J. Tonellato, Medical College of Wisconsin
Dr. Edward D. Zanders, De Novo Pharmaceuticals Ltd.

FUNCTIONAL GENOMICS: Establishing the Function of the ~30,000 Human Genes
Integrated Approaches to Target Validation
In Silico Proteomics to Identify Function
Identifying Metabolic Disease Targets Using Model Organisms
The Rat Genome Database Disease-Centric Initiative
Peptide Display in Functional Genomics
High-Throughput Protein Expression of cDNA Products
Intramers: Promising New Tools in Functional Proteomics

DISEASE GENES FOR DRUG DEVELOPMENT: Finding the Genes That Provide New Targets for Therapeutic Intervention
Using Genomics to Fight Disease
Impact of Homogeneity on Gene Discovery
Novel Therapeutic Programs: Indication Switch and New Lead Discovery
Innovations for the Treatment of Skin Diseases
Correlating Digital Histopathology with Biochip Data
Genomics Approach to Neuropharmacology
Antibacterial Vaccine Design Using Genomics and Proteomics

TARGET VALIDATION: Isolating Tractable Targets Involved in Disease That When Modulated Will Have Therapeutic Benefit Overview
Genetic Dissection of Animal Models for Target Identification
Industrialization of Target Validation: Examples in Hepatitis C, Obesity, and Cancer
From Clinics to Genomics: Phenotyped Populations for Target Validation
Phenotypic Microarrays

FROM PROTEIN STRUCTURE TO DRUG DESIGN: Rational Design of Drugs Based on Understanding 3-D Structure and Chemical Genomic Information
Structural Genomics: Opportunities and Challenges
High-Throughput 3-D Protein Structure Determination
Structural Chemistry-Driven in-Vitro Screening
Realization of Chemical Genomics through in Silico Design
Applications of Chemical Genomics Tools in Drug Discovery and Development
Chemogenomics for Predictive Drug Assessment

7:00am Registration, Exhibit and Poster Set-up, and Light Continental Breakfast

FUNCTIONAL GENOMICS: ESTABLISHING
THE FUNCTION OF THE ~30,000 GENES IN THE HUMAN GENOME

8:30 Chairperson's Opening Remarks
Dr. Trevor Nicholls, Chief Executive Officer, Oxagen Ltd.

8:40 Integrated Approaches to Target Validation
Dr. Trevor Nicholls
Genomics, genetics, and proteomics all offer different ways to identify potential drug targets. No single technology is yet powerful enough to crack the complexity of biology, and an integrated approach is essential to yield the fundamental insights into disease biology that will be required to deliver breakthrough therapies. The strengths and weaknesses of each approach will be compared and a description given of the way in which all these methodologies are used within Oxagen to deliver high-quality, validated targets.

9:10 In Silico Proteomics: Identifying Function Independent of Sequence Homology
Dr. Mary E. Donlan, Director, European Life Science Marketing Simulations and Modeling Product Division, Accelrys
Currently, almost all in silico methods for the functional assignment of gene products rely on some level of sequence homology. We describe a method that uses similar patterns of simulated chemical and biochemical properties to assign function to a protein independent of any sequence-based homology relationships. Simulated properties include prediction of subcellular location, 3-D structural and functional patterns, and response to chemical probes. An example will be given of in silico characterization of chemical response through the combination of HT-modeling and VHTS protocols.

9:40 Identifying Metabolic Disease Targets Using Model Organisms
Dr. Cord E. Dohrmann, Director, Genomics/Target Validation, DeveloGen AG
The recent publication of the human genome has presented unparalleled opportunities for the discovery of novel, therapeutically useful genes that can be used either as targets for drug discovery or as therapeutic agents in their own right. The challenge facing the biopharmaceutical industry is to validate potential targets by assigning true in vivo functions to these genes as rapidly as possible. Model organisms are ideal tools for target identification and validation since gene sequence and function have largely been conserved throughout evolution. DeveloGen AG has developed a broad, enabling technology platform based on model organisms for performing large-scale functional genomics in vivo. The application of its platform to metabolic disease target identification has yielded a number of high potential targets.

11:00 The Rat Genome Database Disease-Centric Initiative
Dr. Peter J. Tonellato, Director, Bioinformatics Research Center, Medical College of Wisconsin
The Rat Genome Database is the first model organism database to use a "disease-centric" perspective to develop, integrate, and incorporate genetic data and information into a research reference database. Our tools, analysis, and data integration processes have been created to couple whole-organism (patho)physiological knowledge derived from the rat scientific community with the genome and functional genetic data recently acquired for rat models. Recent rat projects include a Program in Genomic Applications (PGA) funded by NHLBI to produce designer rat inbred strains and their physiological profile in a spectrum of diseases, the Rat Genome Sequencing Project, and a significant rat gene expression initiative headed by TIGR. These new research agendas will be integrated into the Disease Portals of the Rat Genome Database to provide an environment that allows model comparison from gene to physiological function to disease impact between rat and human. Since rats are the accepted model for drug testing before clinical trials, this ambitious program provides a novel approach to "mapping" recent and ongoing discoveries important to disease immediately into the medical arena.

11:30 Peptide Display in Functional Genomics
Dr. Igor Fisch, Centre For Biotechnology, Swiss Federal Institute of Technology and Selexis SA
The completion of the human genome project has opened novel scientific avenues in functional genomics, structural genomics, and proteomics. These areas have a common goal: the identification of all the proteins acting and cross-talking in a single cell at a defined moment of its lifecycle. The expansion of these areas in bioscience has been facilitated by the rapid development of high-throughput screening methods. Numerous techniques and tools have emerged over the past decade for the identification of small target-specific molecular ligands. These techniques exploit a common feature: the exploration of molecular diversity using combinatorial methods. While chemists developed new methods for rapidly and efficiently synthesizing and screening large collections of small molecules, biologists used recombinant DNA techniques for selecting displayed repertoires. The ability to isolate specific low-molecular-weight compounds is becoming increasingly important as molecular tools for the understanding of protein-protein interactions. To this end, we have developed a novel genetic tool that allows the production of human recombinant proteins at very high yields. This tool is then combined with a phage-display approach for the rapid isolation of candidate low-molecular-weight peptide ligands. An example of the high-yield production of a human recombinant antibody will be discussed as well as the description of a selection procedure for the isolation of specific peptide ligands against a G-protein coupled receptor.

12:00 High-Throughput Protein Expression of cDNA Products as Tools in Functional Genomics
Dr. Magnus Larsson, Royal Institute of Technology
A new high-throughput proteomics strategy based on reporter ligands were developed. The approach has been used for functional analysis of 225 putative gene products predicted from the genome sequence of chromosome 21. An integrated bioinformatics system has been implemented to enable efficient project design, management and analysis of the obtained data.

12:30 RNA-Intramers as Inhibitors of Cytoplasmic Proteins
Dr. Michael Famulok, Principal Investigator, Rheinische Friedrich-Wilhelms Universität
The selection of RNA-aptamers that target specific cytoplasmic proteins is described. Some aptamers inhibit the biological activity of their target protein in vitro. When expressed as "intramers", for example in the cytoplasm of higher eucaryotes, target inhibition is also observed in vivo, resulting in a specific cellular phenotype. Aptamers can also be used for the construction of reporter systems enabling the High-Throughput-Screening of low-molecular weight inhibitors that can replace an aptamer on its bound protein.

DISEASE GENES FOR DRUG DEVELOPMENT: FINDING THE GENES THAT PROVIDE NEW TARGETS FOR THERAPEUTIC INTERVENTION

2:15 Chairperson's Remarks
Dr. Colin W. Dykes, Vice President, Research, Variagenics, Inc.

2:20 Using Genomics to Fight Disease
Dr. Struan Grant, Division Head Cardiovascular and Bone Disease, deCODE genetics
Through large-scale genotyping, deCODE's scientists generate genetic "fingerprints" of each chromosome in every patient. Anomalous chromosome fingerprints shared by related patients with the same disease should indicate the approximate location of a disease gene. Through follow-up analysis using progressively more precise markers, the exact location of the gene can be pinpointed. All genes discovered within this location are screened for mutations by comparing the DNA sequence of healthy and diseased individuals. A gene that is specifically mutated in patients is likely to be the disease gene. The human genetics approach used by deCODE offers a potentially more accurate and efficient method for identifying drug targets. Unlike prevailing strategies based solely on studies of the expression and function of selected genes within the entire genome, deCODE aims first at pinpointing the key mutated genes within the entire genome. New and more effective treatment regimes can thus be built from the bottom up, focusing directly on the full gamut of possible genetic factors behind a given disease.

2:50 Impact of Homogeneity on Gene Discovery: A Success Story in Schizophrenia
Dr. Ariel Darvasi, President and Chief Scientific Officer, IDgene Pharmaceuticals Ltd.
We have recently published a letter in Nature Genetics (Shifman and Darvasi, Nature Genetics 28:309-310, 2001) emphasizing the significant advantages of homogeneous populations for the discovery of genes affecting common diseases. Two major aspects make homogeneous populations efficient for gene discovery: (i) increased levels of linkage disequilibrium and (ii) increased genotypic relative risk due to the homogenous background. We have put our approach to work with Ashkenazi Jews and schizophrenia. We were able to confirm genetic association between the COMT gene on Chromosome 22 and schizophrenia with strong statistical significance. Various candidate genes, such as COMT, have been suggested in the past as candidates that affect susceptibility to schizophrenia. We believe that this is the first strong confirmation of a candidate gene affecting susceptibility to this disease.

3:20 Using Pharmagene TargetEvaluator™ to Initiate Novel Therapeutic Programs: Indication Switch and New Lead Discovery
Dr. Robert A. Coleman, Chief Scientific Officer, Pharmagene plc
Pharmagene TargetEvaluator™ comprises comprehensive human, whole-body expression profiles of an ever-expanding range of genes encoding drug targets in health and disease. It is being used to help initiate drug discovery programs. Its use at Pharmagene has led to the establishment of a range of therapeutic programs both through Indication Switch and New Lead Discovery. The identification and development of two of these programs, potential new treatments for cystic fibrosis and irritable bowel syndrome, will be described.

3:50 From Target Identification and Validation to Product Development: Innovations for the Treatment of Skin Diseases
Dr. J. Peter Halle, Chief Technology Officer, Switch Biotech AG
Switch Biotech identifies the causal factors of skin diseases by means of functional genomics and develops innovative and effective drugs for the treatment of skin diseases and cutaneous ulcers. Recently, we demonstrated that target genes that are upregulated during the normal course of wound healing in healthy volunteers while they are deregulated in diabetic foot ulcer patients play a causal role in the development of the disease. Treatment of diabetic animal models with the corresponding expression vectors increased the wound-healing rate to levels observed in control animals. The genes encode soluble and secreted factors and are suitable for a rapid product development based on the recombinant protein.

5:00 Tissue Characterization by Correlating Digital Histopathology with Biochip Data
Dr. Andres Kriete, Director Imaging Sciences, Tissues Informatics, Inc.
Traditional histopathology based on a visual diagnosis is very limited by its ability to quantify structural, genotype patterns in tissues. We developed a digital image understanding system that allows the hyperquantification of histological sections. Describing all structural components and their relationships opens a way to correlate with genotype biochip expressions. We demonstrate this new capability for tissue characterization in a toxicological study in liver.

5:30 A Genomics Approach to Neuropharmacology
Prof. Hermann Luebbert, Chief Executive Officer, Biofrontera Pharmaceuticals AG
Biofrontera Pharmaceuticals AG is a leading neuroscience company, which applies a deep understanding of gene expression in nervous tissue to expedite research on diseases of the nervous system. Biofrontera's major projects cover Parkinson's disease, chronic pain, schizophrenia, Alzheimer's disease, and stroke. Biofrontera integrates an unsurpassed, proprietary method for RNA pattern analysis, Digital Expression Pattern Display (DEPD®), and highly advanced bioinformatics into a modular process of pharmaceutical drug discovery and development. Biofrontera's unsurpassed database for gene expression changes, occurring during nervous system pathology development, facilitates the selection of new drug targets, identification of lead compounds, and the functional characterization of neuroactive drugs. Biofrontera's foremost project entered phase II clinical trials in November 2001; its next project will enter phase I trials in 2002. These successful projects demonstrate the power of Biofrontera's approach.

6:00 Antibacterial Vaccine Design Using Genomics and Proteomics
Dr. Guido Grandi, Head, Molecular Biology Department, Research Center, Chiron Vaccines
After 2,000 years of practice, vaccinology has proved to be very effective in preventing infectious diseases. However, several human and animal pathogens exist for which vaccines have not yet been discovered. As for other fields of medical sciences, it is expected that vaccinology will greatly benefit from the emerging genomics technologies such as bioinformatics, proteomics, and DNA microarrays. In this presentation, the potential of these technologies applied to bacterial pathogens is analyzed, taking into account the few existing examples of their application in vaccine discovery.

TARGET VALIDATION:
ISOLATING TRACTABLE TARGETS INVOLVED IN DISEASE
THAT WHEN MODULATED WILL HAVE THERAPEUTIC BENEFIT

8:30 Chairperson's Remarks
Dr. Norman J.W. Russell, President, Lynx Therapeutics, Inc.

8:35 Overview
Prof. Graham Boulnois, Venture Partner, Schroder Ventures Life Sciences
Target validation is an ongoing activity in the R&D process with the ultimate validation only occurring once a medicine is established in the market place. Hence at best target validation at any given point in the process can only deliver reduced risk at the down stream decision points. Target validation is a multidisciplinary activity requiring a balanced approach in terms of technology and biology. Competitive advantage comes from successful integration of a range of tools and approaches followed by intelligent application - a single platform is unlikely to dominate. It follows from this that target validation is really a portfolio issue where one seeks to create a risk-balanced portfolio of targets ranging from novel to the well known and generated by a portfolio of approaches. It seems likely that the target portfolio for most companies will be biased towards those targets which are well validated by a combination of internal work, work with partners, research from the academic community and competitor companies.

9:05 Genetic Dissection of Animal Models for Drug Target Identification
Dr. Björn Löwenadler, Chief Scientific Officer, Arexis AB
Summary unavailable at time of printing.

10:05 Industrialization of Target Validation: Examples in Hepatitis C, Obesity, and Cancer
Dr. A. Donny Strosberg, President and Chief Executive Officer, Hybrigenics
With the development of genomics, target prioritization is becoming more and more important. In order to answer this demand, Hybrigenics developed several experiment-based and in silico-based platforms that provide target identification, functional annotation, and validation through a high-throughput three-step process: (i) decipher functional pathways and define protein function by mapping protein interactions, (ii) prioritize the resulting targets using a computer-aided expert analysis platform based on proprietary filtering and annotation tools, and (iii) validate the targets in human cells using specific functional assays designed by the company. This approach has been applied for the in-house drug discovery programs in Hepatitis C, obesity, and cancer and is also made available for collaboration programs.

10:45 From Clinics to Genomics: Phenotyped Populations for Target Validation
Dr. Richard Grosse, Chief Executive Officer, InGene, Institute of Genetic Medicine GmbH
Disease genetics is invoked early in the drug discovery process to help identify and validate key target genes for therapeutic intervention. However, the conventional way of defining genes for multifactorial diseases has failed, mainly because of a critical lack of clinical data that can be linked to gene function. In particular, the lack of data exploring the relationships between genes, environment, and lifestyle prevents progress in understanding common diseases. To fill this gap, InGene has contracted major hospitals in Germany and in Latvia and is collecting patients' clinical-phenotypic, environmental, and social data along with blood/serum samples. InGene assembles the largest database and sample collection for flexible cluster analysis of clinical-phenotypic data to define disease pattern and disease associated genes. InGene's database describes each patient by their clinical-phenotypic, environmental, and lifestyle data. Contrary to all known databases, InGene's proprietary technology derives diagnosis, disease pattern, or pharmacological targets from these data, independently of diagnostic hypothesis. To achieve this goal, PHENOME™ is equipped with a "medical dictionary" ("knowledge database") that represents all known diseases and phenotypes in a computer language. Both the incoming data and known diseases are represented in the same language. This allows the screening of millions of data from individual patients for common disease pattern, diagnoses, clinical coincidences, or potential drug targets. The technology platform developed by InGene provides clinically validated pharmacological and genetic targets for the pharmaceutical and biotechnological industry. In addition, the healthcare sector will use the data to assess disease risks among the population.

11:15 Phenotypic Microarrays: A Robust Metabolic Profiling Technology for Use in the Applications of Pharmacogenomics, Evaluation of a Drug's Mode of Action, Gene Function Studies, and Validation and Optimization of Drug Targets and Leads
Dr. Cori Gorman, Vice President of Research and Development, Biolog
The phenotype of an organism is a result of both its genotype and the surrounding environment. Utilizing cellular metabolic pathway information, an in vitro system has been developed to analyze the components of the metabolic and genetic networks in a single, rapid, and inexpensive assay. Biolog's Phenotypic Microarray (PM) technology provides a powerful new tool for gaining further insight into the drug discovery process by linking phenotypes to specific metabolic pathways in the following areas: target and lead identification, target and lead validation, functional biology, and toxicogenomics. PM technology provides snapshots of cell growth under thousands of different conditions simultaneously, complementing both DNA microarray and proteomics studies. PM technology is actively being applied to the study of infectious diseases, to production, and in a variety of steps in drug development. Uses of the new PM technology include determination of gene function, validation and optimization of drug targets, evaluation of a drug's mode of action and side effects, assessment of cell toxicology, and basic cellular research.

FROM PROTEIN STRUCTURE TO DRUG DESIGN:
RATIONAL DESIGN OF DRUGS BASED ON UNDERSTANDING 3-D STRUCTURE
AND CHEMICAL GENOMIC INFORMATION

1:00 Chairperson's Remarks
Dr. Edward D. Zanders, Vice President, Discovery Genomics, De Novo Pharmaceuticals Ltd.

1:05 Structural Genomics: Opportunities and Challenges
Dr. Peer R.E. Mittl, Institut of Biochemistry, University of Zürich
The immense number of protein sequences generated by more than 80 genome sequencing projects worldwide calls for an initiative to determine three-dimensional structures for as many open reading frames as possible. Different strategies to select promising targets within such an initiative have been suggested. In this context strategies that are tailored to suit the needs of drug development are distinct from strategies that are applied by many basic science, structural genomics projects. Since colonization of the gastric mucosa with the spiral-shaped gram-negative proteobacterium Helicobacter pylori is probably the most common chronic infection in humans, we selected promising structural genomics targets from this organism. Target selection strategies and preliminary results in structure determination and functional analysis in our group, as well as within a newly founded Swiss National Centre of Competence in structural biology, will be presented and discussed.

1:35 High-Throughput 3-D Protein Structure Determination
Dr. Udo Heinemann, Forschungsgruppe Kristallographie, Max-Delbruck-Centrum für Molekulare Medizin
I will provide an update on the status of the Berlin-based structural genomics project, the Protein Structure Factory. I intend to describe the technological infrastructure for high-throughput protein structure analysis set up there and present first results. A strategy to commercialize the approach of the Protein Structure Factory will also be mentioned.

2:05 Structural Chemistry-Driven in-Vitro Screening
Dr. Martin Norin, Director Structural Chemistry, Biovitrum
Over the last few years, the utilization of protein structural information in drug discovery research has matured and is today applied throughout the process, ranging from genomics-derived target identification and selection to the final design of suitable drug candidates. An especially powerful methodology has arisen from the clear synergies of the combination of target structural information with combinatorial chemistry. Several structural genomics initiatives have recently been started and are now generating 3-D structures of target molecules at an unprecedented rate that will provide a wealth of novel information that can be utilized for rational drug design.

3:05 The Realization of Chemical Genomics through in Silico Design
Dr. Edward D. Zanders
Modern pharmaceutical research is underpinned by chemical genomics, a high-throughput approach to biology and chemistry. Given the large number of possible targets that are being identified by genomics, it is inconceivable that high-throughput screening of synthesized compound libraries will be able to match the challenge of identifying "a small molecule for every protein." This realization is driving the search for in silico methods of compound identification and screening, and these technologies will be described in this talk within the context of genomics and proteomics.

3:30 Chemogenomics for Predictive Drug Assessment
Dr. Les Browne, Chief Operating Officer, Iconix (in collaboration with Incyte Genomics)
Genomics, ultrahigh-throughput screening, and other technologies are creating an abundance of diverse data for drug discovery. However, extracting knowledge relevant for predicting pharmacological and toxicological effects is still a major unmet challenge. We are building a large-scale reference database and informatics system that integrates chemical and genomic information about known drugs and toxicants with their known biological responses.

4:00 Prioritising the Proteome: Identifying Pharmaceutically Relevant Targets by Linking Sequence to Function through 3D Structure
Dr. John Overington, Vice President, Drug Discovery, Inpharmatica
Inpharmatica is focussed on the application of protein 3-D structural data to the identification of distantly related homologs of pharmaceutically important gene families. We have developed a combined bioinformatics and chemoinformatics platform that significantly improves the yield and quality of functional annotation and correlates this annotation with an estimation of druggability. We will describe some specific examples of the application of this technology to the target discovery process.

Registrants of Pharmacogenomics/Pharmacoproteomics Europe are invited to attend.

CALL FOR POSTERS
Cambridge Healthtech Institute encourages attendees to gain further exposure by presenting their work in the poster sessions. Please fill out the registration form, with the poster title and primary author. To ensure inclusion in the conference binder, a one-page summary must be submitted and registration must be paid in full by April 5, 2002. Click here for poster instructions

HOTEL INFORMATION
Hilton Munich Park
Am Tucherpark 7
D-80538 Munich, Germany
T: 49-89-3845-0
F: 49-89-3845-2588
Room Rates: DM 420,00/S • 480,00/D
Please call the hotel directly to make your room reservation. Identify yourself as a Cambridge Healthtech Institute conference attendee to receive the reduced room rate. Reservations made after the cut-off date or after the group room block has been filled (whichever comes first) will be accepted on a space-and-rate-availability basis. Rooms are limited, so please book early.

CALL FOR SPONSORS AND EXHIBITORS
Certainly, the importance of relating genomic data to the drug discovery and development process is immeasurable. This conference will take particular interest in using case studies to help estimate the actual benefit of integrating genomic data into drug research and clinical practices. We strongly encourage any company with services or products related to target validation, chemical genomics, animal models, lab chips, proteomics, structural genomics, disease research, to consider sponsoring or exhibiting at this event. Sponsorship is the best way to prominently elevate your company's presence and influence at this conference. Although exhibit space can be purchased separately, many sponsorship packages also include a booth.

For more information on sponsorship opportunities, please contact Angela Parsons at 781-972-5467 or aparsons@healthtech.com.

To reserve a booth, please contact Pam Crane at 781-972-5431 or pcrane@healthtech.com.

Impact of Genomics on Medicine exhibitors
The following companies are registered to exhibit as of 5/13/02:

Pharmacogenomics/Pharmacoproteomics Europe Exhibitors
The following companies are registered to exhibit as of 5/13/02:

TRAVEL INFORMATION
Special Airline Discounts Available
Special zone and discount fares have been established on United Airlines for this conference. Please call United Airlines Meeting Reservations Center directly at 800-521-4041. You must reference ID #579YS.

7:00pm Gala Reception at the Bavarian Residence
	This elegant reception is hosted by the State of Bavaria. The host will be the Bavarian Vice Minister for Economic Affairs, Transport and Technology, Mr. Hans Spitzner. The reception will be held at the Nibelungensaal of the Residence, Munich. Pick up your complimentary admission ticket at the registration desk at the conference. Shuttle buses will be provided.

Revised Program

	Upcoming Conferences	Order Binder